Get the Stockscreener App
12.30
0.65%
0.08
After Hours:
12.31
0.010
+0.08%
Atrium Therapeutics Inc stock is traded at $12.30, with a volume of 88,243.
It is up +0.65% in the last 24 hours and down -3.53% over the past month.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
See More
Previous Close:
$12.22
Open:
$12.26
24h Volume:
88,243
Relative Volume:
0.34
Market Cap:
$210.40M
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-5.1789
EPS:
-2.375
Net Cash Flow:
$-502.70M
1W Performance:
-8.00%
1M Performance:
-3.53%
6M Performance:
-83.06%
1Y Performance:
-61.20%
1-Day Range:
$12.05
$12.40
1-Week Range:
$12.05
$13.44
52-Week Range:
$11.40
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Name
Atrium Therapeutics Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
12.30 | 209.03M | 10.73M | -455.74M | -502.70M | -2.375 |
VRTX
Vertex Pharmaceuticals Inc
|
477.08 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.45 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.93 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.44 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.14 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Wells Fargo | Overweight |
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Atrium Therapeutics Inc Stock (RNA) Latest News
Atrium’s ATR-1072 gains IND clearance for PRKAG2 syndrome - BioWorld News
Atrium Therapeutics Receives FDA Clearance for ATR 1072, Launches First Clinical Trial Targeting PRKAG2 Syndrome - Minichart
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug - dicardiology.com
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
Atrium Therapeutics Secures FDA Clearance for ATR 1072 Trial - grafa.com
Atrium gets FDA clearance for PRKAG2 syndrome trial - Investing.com UK
FDA clears Atrium Therapeutics' IND for ATR 107... - Pluang
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - PR Newswire
Atrium Therapeutics (RNA) Slips 3.5% as Biotech Headwinds IntensifySuperTrend - dars.gov.et
Enterprise value to revenue forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to earnings forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to sales forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Atrium Therapeutics Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
RNA News | ATRIUM THERAPEUTICS INC (NASDAQ:RNA) - ChartMill
Atrium Therapeutics, Inc.(NasdaqGS:RNA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Company Poised for Nearly 90% Upside - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Growth Benchmark - marketscreener.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Clinical ProgressFiscal Year Earnings - dars.gov.et
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell Microcap Index - marketscreener.com
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Index - marketscreener.com
RNA Forecast — Price Target — Prediction for 2027 - TradingView
Atrium Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNA) - TradingView
RNA Technical Analysis & Stock Price Forecast - Intellectia AI
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics Faces Modest Pullback as Support Levels Under ScrutinyIV Expansion Alert - DonanımHaber
Arbiter Partners Capital Management LLC's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Cantor Fitzgerald Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Stage; Stock Inches HigherOperating Margin Analysis - Město Břeclav
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pipeline Progress - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status; Stock Drops on Cash Burn ConcernsEPS Miss Report - newsline.com
Atrium Therapeutics (RNA) Slips 2.28% as Biotech Sector Faces HeadwindsPCR Moving Average - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amidst Clinical Progress and Cost DisciplinePeak Earnings Alert - newsline.com
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational Discipline - dars.gov.et
RNAAtrium Therapeutics Inc Forecast, Target Price - Finviz
RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Drives EPS Beat, but Stock SlipsReturn On Capital - dars.gov.et
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance
Atrium Therapeutics Inc. (RNA) Holds Steady Near Resistance as Momentum BuildsCash Flow Strong Stocks - newsline.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 90.99% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor Sentiment - Newser
Atrium Therapeutics (RNA) Stages a Recovery: Testing Key Resistance at $13.69Crowd Stock Picks - Newser
Atrium Therapeutics Inc - Reuters
RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus
RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan
Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo
Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo
Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network
Atrium Therapeutics Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atrium Therapeutics Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
0.27%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):